Here you will find the very latest program information for the Washington Vaccine Forum 2010. It's not too late for your input, please complete a Shape Your Event form, or contact amanda@phacilitate.co.uk with any suggestions.
|
|
|
|
Day 1 - Monday 25th January 2010
|
|
Morning plenary session
How are we doing with pandemic planning?
• Are we making the right decisions on vaccine strategy and funding to rapidly deal with outbreaks of new strains?
|
|
Followed by your choice of three highly interactive parallel sessions:
|
|
Focus session 1
Clinical trial strategy and regulatory pathways for pandemic influenza vaccines
|
OR | Focus session 2
Optimizing your value proposition and positioning strategy for new vaccines
• Case studies of recent launches
|
OR | Workshop *
Vaccines for major public health needs: Analyzing the latest clinical results for nosocomial infections
|
|
Followed by afternoon plenary session
|
|
How will pandemic influenza change the technology, manufacturing and economic landscape of the vaccine industry?
|
|
| Day 2 - Tuesday 26th January 2010 |
|
Morning plenary session
Defining the business models that are most likely to deliver affordable vaccines for major global unmet needs
|
|
Followed by your choice of three highly interactive parallel sessions:
|
|
Focus session 1
Prophylactic and therapeutic vaccines for chronic viral infectious diseases: Where are the breakthroughs in terms of understanding of immunity?
|
OR | Focus session 2
What evidence is now available showing commercial promise for cell culture manufacturing?
|
OR | Workshop*
How are translational science and biomarkers being applied to development pathways for novel adjuvants and delivery systems?
• What is the regulatory response?
|
|
Followed by afternoon plenary session
|
|
Afternoon plenary session
Therapeutic cancer vaccines: Now that licensure is a reality, how will these products be commercialized, and what does this mean for the vaccines sector as a whole?
|
|
| Day 3 - Wednesday 27th January 2010 |
|
Morning plenary session
Analyzing the impact of the Obama administration’s healthcare regime on the evolution of priorities for vaccines
|
|
Followed by your choice of three parallel sessions:
|
|
Focus session 1
Evaluating progress in influenza vaccine R&D: Advancing 2nd generation DNA vaccines, and striving for cross protection and the universal vaccine
|
Focus session 2
How close are malaria and flavivirus vaccines to the market?
• Analyzing the latest clinical data for breakthroughs and next steps
|
OR | Workshop*
Financing and partnerships to bring novel enabling technologies to market for developed and developing world vaccine needs
|
